Medivolve Inc MEDVF

Spectral Analytics to Launch Patient Trial for

[MrTAteam]

COVID-19 Treatment.

"A clinical research site has been selected and which will enroll 20 subjects in the initial study, with plans to expand the trial if the initial 20 subject trial demonstrates safety and efficacy in treating COVID-19.

“This study is unique in that we have focused on identifying viruses that have similar characteristics, and are now exploring the potential of combining these drugs to create new effective treatments,” explained Steven Adler, CEO of Spectral Analytics. “The goal is to maximize the efficacy of the drugs in combating the virus, while minimizing the time required for testing, in order to rapidly get these drugs to those who need them most. Because these drugs are already FDA-approved for the treatment of other viruses, these drugs will also be more inexpensive to bring to market than newly-created drugs in a cost-effective manner for the patients.”
https://www.einnews.com/pr_news/517296175/spectral-analytics-to-launch-patient-trial-for-covid-19-treatment

[MoneyGuy101]

Should hear from this any day now. 

[Sonboss]

With an fda approval of this treatment,  qsc will have 40% of the revenu ? Am i right?

[INXS1]

only if : The closing of the transaction to acquire a 40-per-cent interest in Spectral is conditional on Spectral securing IRB approval for human trials and submission of a successful in vitro study to the FDA satisfactory to Questcap and other customary closing conditions.

[Sonboss]

Thank you for that precision!